GSA Capital Partners LLP lowered its stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) by 36.8% during the third quarter, according to the company in its most recent disclosure with ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), retaining the price target ...

Barclays analyst Peter Lawson raised the firm’s price target on Biomea Fusion (BMEA) to $11 from $9 and keeps an Equal Weight rating on ...

Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral ...

On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, MarketBeat Ratings reports.

On Tuesday, Truist Securities adjusted its stance on Biomea Fusion Inc. (NASDAQ:BMEA) stock, moving from a Buy to a Hold rating. This decision comes in the wake of a clinical hold... On Monday, H ...

Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a move near 6.1%, or 75c, after results are released.

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...